A5045254285- Cancer Immunotherapy and Biomarkers
- Cell Adhesion Molecules Research
- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Neuropeptides and Animal Physiology
- Peptidase Inhibition and Analysis
- Cancer Research and Treatments
- Lung Cancer Treatments and Mutations
- Wnt/β-catenin signaling in development and cancer
- Cell death mechanisms and regulation
- Erythrocyte Function and Pathophysiology
- Phagocytosis and Immune Regulation
- Glycosylation and Glycoproteins Research
- Radiopharmaceutical Chemistry and Applications
University of Groningen
2016-2020
University Medical Center Groningen
2016-2020
Amsterdam UMC Location University of Amsterdam
2016
University of Amsterdam
2016
PD-L1-blocking antibodies produce significant clinical benefit in selected cancer patients by reactivating functionally-impaired antigen-experienced anticancer T cells. However, the efficacy of current is potentially reduced 'on-target/off-tumor' binding to PD-L1 widely expressed on normal This lack tumor selectivity may induce a generalized activation all cells which explain frequent occurrence autoimmune-related adverse events during and after treatment. To address these issues, we...
The unrestrained growth of tumor cells is generally attributed to mutations in essential control genes, but are also affected by, or even addicted to, signals from the microenvironment. As therapeutic targets, these extrinsic may be equally significant as mutated oncogenes. In multiple myeloma (MM), a plasma cell malignancy, most tumors display hallmarks active Wnt signaling lack activating Wnt-pathway mutations, suggesting activation by autocrine ligands and/or paracrine Wnts emanating bone...
Antibodies that block PD-L1/PD-1 immune checkpoints restore the activity of functionally-impaired antitumor T cells. These antibodies show unprecedented clinical benefit in various advanced cancers, particularly melanoma. However, only a subset cancer patients responds to current PD-L1/PD-1-blocking strategies, highlighting need for further advancements PD-L1/PD-1-based immunotherapy. Here, we report on novel approach designed combine PD-L1 checkpoint inhibition with tumor-selective...
Cancer cells overexpress CD47 to subvert phagocytic elimination and evade immunogenic processing of cancer antigens. Moreover, overexpression inhibits the antibody-dependent cellular phagocytosis (ADCP) cytotoxicity (ADCC) activities therapeutic anticancer antibodies. Consequently, CD47-blocking antibodies have been developed overcome immunoevasive cell-expressed CD47. However, wide-spread expression on normal forms a massive "antigen sink" that potentially limits sufficient tumor accretion...
Abstract PD-L1-blocking antibodies produce significant clinical benefit in selected cancer patients by reactivating functionally-impaired anticancer T cells. However, their efficacy is potentially reduced ‘on-target/off-tumor' binding to PD-L1 widely expressed on normal This lack of tumor selectivity induces a generalized activation all antigen-experienced cells as evidenced frequent autoimmune-related adverse events during and after treatment. To address these issues, we constructed...